Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.: Annual Revenue Growth Compared

Teva vs. Amneal: A Decade of Revenue Divergence

__timestampAmneal Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201478562300020272000000
Thursday, January 1, 201586628000019652000000
Friday, January 1, 2016101822500021903000000
Sunday, January 1, 2017103365400022385000000
Monday, January 1, 2018166299100018854000000
Tuesday, January 1, 2019162637300016887000000
Wednesday, January 1, 2020199252300016658000000
Friday, January 1, 2021209366900015878000000
Saturday, January 1, 2022221230400014925000000
Sunday, January 1, 2023239360700015846000000
Monday, January 1, 202416544000000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Revenue Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Amneal Pharmaceuticals, Inc. have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, Teva's revenue experienced a notable decline of approximately 22%, dropping from its peak in 2017. This downturn reflects challenges in the generic drug market and increased competition. In contrast, Amneal Pharmaceuticals has demonstrated a robust growth trajectory, with revenues nearly tripling, marking a 205% increase over the same period. This growth underscores Amneal's strategic expansions and successful product launches. The year 2023 highlights this divergence, with Amneal reaching its highest revenue point, while Teva continues to navigate its recovery path. These trends offer a compelling narrative of resilience and adaptation in the pharmaceutical industry, providing valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025